Fedratinib: First Approval

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

(2017) Claire N Harrison et al.   Lancet Haematology

Development of TG101348 for the treatment of JAK2-driven malignancies

(2017) J. Hood et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

(2015) Clodagh Keohane et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

(2015) Catriona Jamieson et al.   Journal of Translational Medicine

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

(2015) A Pardanani et al.   Blood Cancer Journal

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

(2015) Animesh Pardanani et al.   JAMA Oncology

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms

(2014) Olga Pozdnyakova et al.   MODERN PATHOLOGY

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers

(2013) Meng Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

(2013) T Zhou et al.   LEUKEMIA

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

(2010) A Pardanani et al.   LEUKEMIA

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL